Myriad, Pharmacia Ink Pharmacogenomic Partnership | GenomeWeb

NEW YORK, Oct. 30 - Myriad Genetics and drug giant Pharmacia have entered into a pharmacogenomics alliance that has been designed ultimately to develop and commercialize technologies to help researchers begin to apply personalized medicine, Myriad said on Tuesday.

Terms of the alliance, which is open-ended, call for Myriad, of Salt Lake City, to use its gene-sequencing technology to analyze SNPs from a variety of populations, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.